Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

593 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved Annotation of Asthma Gene Variants with Cell Type Deconvolution of Nasal and Lung Expression-Quantitative Trait Loci.
El-Husseini ZW, Karp T, Lan A, Gillett TE, Qi C, Khalenkow D, van der Molen T, Brightling C, Papi A, Rabe KF, Siddiqui S, Singh D, Kraft M, Beghé B, Joubert P, Bossé Y, Sin D, Cordero AH, Timens W, Brandsma CA, Hao K, Nickle DC, Vonk JM, Nawijn MC, van den Berge M, Gosens R, Faiz A, Koppelman GH. El-Husseini ZW, et al. Among authors: papi a. Am J Respir Cell Mol Biol. 2025 Jan 21. doi: 10.1165/rcmb.2024-0251MA. Online ahead of print. Am J Respir Cell Mol Biol. 2025. PMID: 39836087
Blood Eosinophil Count Stability in COPD and the Eosinophilic Exacerbator Phenotype.
Baraldi F, Bartlett-Pestle S, Allinson JP, Macleod M, Mah J, Bloom C, Brady-Green A, Marion A, Papi A, Wedzicha JA, Finney LJ. Baraldi F, et al. Among authors: papi a. Am J Respir Crit Care Med. 2025 Jan 15. doi: 10.1164/rccm.202407-1287RL. Online ahead of print. Am J Respir Crit Care Med. 2025. PMID: 39813681 No abstract available.
The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper.
Agache I, Adcock IM, Akdis CA, Akdis M, Bentabol-Ramos G, van den Berge M, Boccabella C, Canonica WG, Caruso C, Couto M, Davila I, Drummond D, Fonseca J, Gherasim A, Del Giacco S, Jackson DJ, Jutel M, Licari A, Loukides S, Moreira A, Mukherjee M, Ojanguren I, Palomares O, Papi A, Perez de Llano L, Price OJ, Rukhazde M, Shamji MH, Shaw D, Sanchez-Garcia S, Testera-Montes A, Torres MJ, Eguiluz-Gracia I. Agache I, et al. Among authors: papi a. Allergy. 2024 Dec 16. doi: 10.1111/all.16436. Online ahead of print. Allergy. 2024. PMID: 39676750
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS; COURSE study investigators. Singh D, et al. Among authors: papi a. Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6. Lancet Respir Med. 2025. PMID: 39653044 Clinical Trial.
GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.
Singh D, Stockley R, Anzueto A, Agusti A, Bourbeau J, Celli BR, Criner GJ, Han MK, Martinez FJ, Montes de Oca M, Ozoh OB, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Troosters T, Wedzicha J, Zheng J, Volgelmeier C, Halpin D. Singh D, et al. Among authors: papi a. Eur Respir J. 2024 Dec 5:2401603. doi: 10.1183/13993003.01603-2024. Online ahead of print. Eur Respir J. 2024. PMID: 39638416
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS).
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Dakin P, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM. Bhatt SP, et al. Among authors: papi a. Respir Med. 2025 Jan;236:107846. doi: 10.1016/j.rmed.2024.107846. Epub 2024 Oct 30. Respir Med. 2025. PMID: 39481660 Free article. Clinical Trial.
Call to Action: How Can We Promote the Development of New Pharmacologic Treatments in Chronic Obstructive Pulmonary Disease?
Belz DC, Putcha N, Alupo P, Siddharthan T, Baugh A, Hopkinson N, Castaldi P, Papi A, Mannino D, Miravitlles M, Han M, Fabbri LM, Montes de Oca M, Krishnan JA, Singh D, Martinez FJ, Hansel NN, Calverley P. Belz DC, et al. Among authors: papi a. Am J Respir Crit Care Med. 2024 Dec 1;210(11):1300-1307. doi: 10.1164/rccm.202311-2180PP. Am J Respir Crit Care Med. 2024. PMID: 39405496 No abstract available.
593 results